We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Method Developed for More Effective Noninvasive Prostate Cancer Screening

By LabMedica International staff writers
Posted on 16 Sep 2014
Comparing healthy volunteers and prostate cancer (PrCa) patients, researchers have successfully shown that their new method, which builds on the use of SERS spectroscopy of silver nanoparticles mixed with blood samples, could reveal cases of cancer.

A team of researchers led by Prof. More...
Shaoxin Li, of Guangdong Medical College (Guangdong province, China), has demonstrated potential of a new noninvasive method to screen for PrCa based on combining of the existing technique of serum surface-enhanced Raman scattering (SERS) with the new sophisticated analysis technique called support vector machine (SVM). Applying the combined SERS-SVM system to blood samples collected from 68 healthy volunteers and 93 people clinically confirmed to have PrCa, their technique identified the PrCa cases with 98.1% accuracy.

If the technique proves safe and effective in clinical trials, it may become an effective method available to patients and their doctors for improving early diagnosis of PrCa. “The results demonstrate that label-free serum SERS analysis combined with SVM diagnostic algorithm has great potential,” said Prof. Li, “Compared to traditional screening methods, this method has the advantages of being noninvasive, highly sensitive, and very simple.”

The blood test for elevated levels of PSA (prostate specific antigen) commonly used for PrCa screening and monitoring is far from perfect as elevated PSA levels can be caused by many factors unrelated to cancer. This contributes to over-diagnosis, uncomfortable tissue biopsies, and other unnecessary treatment, which can be costly and carry significant side-effects. Because of this, the US Preventative Services Task Force now recommends against PSA-based screening for PrCa.

Other scientists have considered applying SERS to cancer detection as it would seem to enable detection of the subtle marker signals. The challenge, said Prof. Li, was that the signal differences between the serum samples taken from the healthy volunteers and the PrCa patients were too subtle to detect. So his team employed also the powerful spectral data processing algorithm SVM – and found it to be effective. While the work is preliminary, it demonstrates that the method has good potential for PrCa screening. The next research step, added Prof. Li, is to refine the method and explore whether it can distinguish cancer staging.

The method, described by S. Li et al, was published in the journal Applied Physical Letters, September 2, 2014, online.

Related Links:

Guangdong Medical College



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Silver Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.